Spots Global Cancer Trial Database for Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Official Title: Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Study ID: NCT03850418
Conditions
Interventions
Study Description
Brief Summary: Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Henry ford hospital, Detroit, Michigan, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
